Craig R Travis

US Patent:

6566560, May 20, 2003

Filed:

Aug 13, 2001

Appl. No.:

09/928683

Inventors:

Craig R. Travis - South Miami FL

Assignee:

Immugen Pharmaceuticals, Inc. - Miami FL

International Classification:

C07C 3318

US Classification:

568715, 568716, 560 8, 560103, 560104, 560105

Abstract:

The invention provides a resorcinol derivative and a method of using the resorcinol derivative to attenuate the growth of a neoplasm.

US Patent:

6541510, Apr 1, 2003

Filed:

Sep 28, 2001

Appl. No.:

09/967341

Inventors:

Craig R. Travis - South Miami FL

Assignee:

Immugen Pharmaceuticals, Inc. - South Miami FL

International Classification:

A61K 31353

US Classification:

514456

Abstract:

The invention provides a method, compounds, and compositions for inhibiting the replication or proliferation of a virus. In accordance with the invention, at least one cannabichromene derivative is exposed to the virus, a host cell, or an infected cell under conditions sufficient to inhibit the replication or proliferation of the virus.

US Patent:

7105685, Sep 12, 2006

Filed:

Dec 22, 2002

Appl. No.:

10/328242

Inventors:

Craig R. Travis - South Miami FL, US

International Classification:

C07D 311/80
C07D 311/04
C07D 311/78

US Classification:

549390, 549200, 549356, 549381, 549385, 549388, 549389, 549391

Abstract:

The invention provides cannabinol derivatives and pharmaceutical preparations thereof.

US Patent:

8586767, Nov 19, 2013

Filed:

Jan 23, 2012

Appl. No.:

13/355676

Inventors:

Craig Rick Travis - South Miami FL, US

International Classification:

C07D 311/80
A01N 43/16

US Classification:

549390, 514454

Abstract:

This invention discloses cannabinoid derivatives and pharmaceutical uses thereof.

US Patent:

20020137802, Sep 26, 2002

Filed:

Sep 28, 2001

Appl. No.:

09/967353

Inventors:

Craig Travis - South Miami FL, US

International Classification:

A61K031/05

US Classification:

514/731000, 435/002000

Abstract:

The invention provides a method for attenuating the aggregation and/or activation of blood platelets within a blood product. In accordance with this method, a cannabinoid or resorcinolic compound is introduced into the blood product under conditions sufficient to inhibit the aggregation and/or activation of blood platelets within the blood product. The invention also pertains to the use of a cannabinoid or resorcinolic compound to prepare a composition suitable for inhibiting the activation and/or aggregation of blood platelets and to such compositions. The invention also pertains to a method of selectively inhibiting COX-1 and thromboxane synthase within a cell or blood platelet.

US Patent:

20030171372, Sep 11, 2003

Filed:

Jan 16, 2003

Appl. No.:

10/345714

Inventors:

Craig Travis - South Miami FL, US

Assignee:

Immugen Pharmaceuticals, Inc. - South Miami FL

International Classification:

A61K031/5377
A61K031/382
A61K031/353

US Classification:

514/233500, 514/312000, 514/432000, 514/456000, 544/145000, 544/151000, 546/153000, 549/023000, 549/399000

Abstract:

The invention provides a method, compounds, and compositions for inhibiting the replication or proliferation of a virus. In accordance with the invention, at least one cannabichromene derivative is exposed to the virus, a host cell, or an infected cell under conditions sufficient to inhibit the replication or proliferation of the virus.

US Patent:

20030232101, Dec 18, 2003

Filed:

Mar 18, 2003

Appl. No.:

10/391845

Inventors:

Craig Travis - South Miami FL, US

Assignee:

Immugen Pharmaceuticals, Inc. - South Miami FL

International Classification:

A61K031/353
A61K035/78

US Classification:

424/776000, 514/455000, 514/454000

Abstract:

In one aspect, the invention provides a method for preventing the transmission of HIV from one individual to another. In accordance with the method, a pharmacologically-acceptable composition including at least one resorcinol derivative compound and/or cannabinoid (e.g., cannabinol derivatives, 8-THC derivatives, cannabichromene derivatives, cannabidiol derivatives, cannabigerol derivatives) (including combinations thereof) is administered topically to a first individual harboring HIV, or to a second individual at risk of infection with HIV, proximate in time with contact between the first individual and the second individual. The invention also provides topical formulations of at least one resorcinol and/or cannabinoid and water insoluble polymers as hydrogels.

US Patent:

20040138315, Jul 15, 2004

Filed:

Dec 16, 2003

Appl. No.:

10/738457

Inventors:

Craig Travis - South Miami FL, US

Assignee:

Immugen Pharmaceuticals, Inc. - South Miami FL

International Classification:

A61K031/05
A01N001/02

US Classification:

514/731000, 435/002000

Abstract:

The invention provides a method for attenuating the aggregation and/or activation of blood platelets within a blood product. In accordance with this method, a cannabinoid or resorcinolic compound is introduced into the blood product under conditions sufficient to inhibit the aggregation and/or activation of blood platelets within the blood product. The invention also pertains to the use of a cannabinoid or resorcinolic compound to prepare a composition suitable for inhibiting the activation and/or aggregation of blood platelets and to such compositions. The invention also pertains to a method of selectively inhibiting COX-1 and thromboxane synthase within a cell or blood platelet.